肿瘤细胞治疗研究
ALL SOURCES
Preclinical evaluation of the ROR1-targeting antibody-drug conjugates zilovertamab vedotin and VLS-211 against B-cell ALL patient-derived xenografts.
尽管过去60年急性淋巴细胞白血病（ALL）的生存率已显著提高，但不同分子亚型和风险类别的预后仍存在差异，仍有相当数量的患者难以治疗。
In vitro characterization of a novel anti-GD2/ROR1 bispecific antibody exhibiting tumor cell killing efficacy in neuroblastoma cross-cancer activity i
G/R-001 BsAb可同时结合GD2和ROR1，并在体外显示出显著的抗肿瘤活性。这些结果为G/R-001作为新型抗肿瘤治疗药物的进一步开发提供了有力的实验证据。
Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma.
我们的结果表明，分泌细胞因子的溶瘤病毒联合CAR-NK细胞是一种治疗高危NB的新型有效免疫治疗方法。
Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts.
在体内，与单用 anti-ROR1 CAR exPBNK 相比，anti-ROR1 CAR exPBNK 联合 N-803 显著（p < 0.05）提高了人 ROR1⁺ NB 异种移植 NSG 小鼠的生存率。
共 4 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
